Filing Details

Accession Number:
0001062993-24-003738
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-20 17:37:44
Reporting Period:
2024-02-15
Accepted Time:
2024-02-20 17:37:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1894562 Prime Medicine Inc. PRME () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219039 Keith Crandell C/O Arch Venture Partners Ix, Llc
8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1229592 Steven Gillis C/O Arch Venture Partners
8755 West Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1569248 Kristina Burow 8755 W. Higgins Road,Suite 1025
Chicago IL 60631
No No Yes No
1757011 Arch Venture Fund X, L.p. 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1757017 Arch Venture Fund X Overage, L.p. 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1768905 Arch Venture Partners X Overage, L.p. 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1769012 Arch Venture Partners X, Llc 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
1782583 Arch Venture Partners X, L.p. 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-15 3,200,000 $6.25 3,200,000 No 4 P Indirect By ARCH Venture Fund XII, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By ARCH Venture Fund XII, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,128,297 Indirect By ARCH Venture Fund X, L.P.
Common Stock 6,128,297 Indirect By ARCH Venture Fund X Overage, L.P.
Footnotes
  1. Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
  2. Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
  3. ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose.
  4. Represents shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the general partner of AVP XII LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.